Black-White NSCLC Survival Gap Widens in Counties With Greater Racial Inequity

Why It Matters

The findings reveal that systemic inequities, not just clinical factors, drive survival differences, urging health systems and policymakers to address structural racism to improve cancer outcomes for Black patients.

Key Takeaways

• 10‑point Black‑White survival gap in most segregated counties
• Deprivation lowers stage‑appropriate treatment for Black and White patients
• Structural racism index correlates with reduced two‑year survival for Black patients
• No significant survival difference observed in low‑segregation counties
• Findings exclude younger, Medicare Advantage, and uninsured lung‑cancer patients

Pulse Analysis

Non‑small cell lung cancer remains the leading cause of cancer death in the United States, yet its mortality profile is unevenly distributed across racial lines. While overall incidence has declined, Black patients continue to face lower rates of early‑stage diagnosis and reduced access to guideline‑concordant therapies. Recent scholarship suggests that these gaps are rooted not only in individual socioeconomic status but also in the broader fabric of structural racism that shapes housing, education, employment, and health‑care access at the community level.

The JAMA Network Open analysis leveraged SEER‑Medicare data from 2013‑2019, encompassing over 54,000 patients aged 67 and older. By applying two indices—the Structural Racism Effect Index and the County Structural Racism (CSR) index—the researchers isolated the impact of racial inequity on three key outcomes: localized diagnosis, stage‑appropriate treatment, and two‑year survival. While county deprivation uniformly lowered odds of optimal care for both Black and White patients, only the CSR index produced a pronounced interaction: Black patients in high‑dissimilarity counties experienced a 10‑point survival deficit, whereas White patients saw no comparable loss. This paradox underscores how segregation amplifies barriers uniquely for Black communities.

The study’s implications extend beyond academic insight. Quantifying structural racism offers a pragmatic tool for health systems to pinpoint geographic hotspots where interventions—such as targeted screening programs, transportation subsidies, and culturally competent care pathways—could narrow survival gaps. However, the analysis is limited to fee‑for‑service Medicare beneficiaries, excluding younger, uninsured, and Medicare Advantage populations who may face even steeper disparities. Policymakers must therefore broaden data collection and invest in community‑level reforms to dismantle the systemic forces that perpetuate inequitable cancer outcomes.